{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-164328","form_type":"8-K","ticker":"TRAX","cik":"0002091349","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.488298+00:00","generated_at":"2026-05-15T05:23:55.311056+00:00","sec_items":["1.01","2.01","3.02","3.03","5.03","5.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement","bullets":["Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.","Private placement of ~10.5M shares at $13.81: company issued 5.79M shares (~$80M proceeds) and selling stockholder sold 4.71M shares.","Entered Separation and Distribution and Transition Services Agreements with AnaptysBio to govern asset/liability split and post-spin operations.","First Tracks received $100M cash and rights to up to $35M in milestone payments from Vanda Pharmaceuticals collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-164328","json":"https://secwatch.observer/filing/0001193125-26-164328.json","markdown":"https://secwatch.observer/filing/0001193125-26-164328.md","text":"https://secwatch.observer/filing/0001193125-26-164328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:23:55.311056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a45008cb1e1fe1b7379f1bd6d2da84ffa83caca","claim":"First Tracks Biotherapeutics, Inc.: Amended and Restated Certificate of Incorporation became effective in connection with the Spin-Off.","evidence_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","confidence":0.9},{"claim_id":"a88750d1fb66a91688e3a72d2d96f4c2f9e9c9e2","claim":"First Tracks Biotherapeutics, Inc.: Bylaws became effective in connection with the Spin-Off.","evidence_excerpt":"Our Bylaws (the “Bylaws”) also became effective in connection with the Spin-Off.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","confidence":0.9},{"claim_id":"3a58de5f73c71c9b0f1d5a66a86ee0ead88512a3","claim":"First Tracks Biotherapeutics, Inc. completed a disposition involving AnaptysBio, Inc. (closed 2026-04-20).","evidence_excerpt":"On the Distribution Date, AnaptysBio completed the Spin-Off.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","confidence":0.95},{"claim_id":"1b2ad13ee33d11bd021bf1c882ba15bd88328ac7","claim":"First Tracks Biotherapeutics, Inc. entered into Transition Services Agreement with AnaptysBio.","evidence_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","confidence":0.9},{"claim_id":"631470f7340f756208beb551f2662015c19a999e","claim":"First Tracks Biotherapeutics, Inc. entered into Separation and Distribution Agreement with AnaptysBio.","evidence_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change, material_agreement","same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: governance_change, material_agreement","same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001104659-26-057915","ticker":"SUJA","company_name":"SUJA LIFE, INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026","event_type":"other_material","sec_items":["1.01","3.02","3.03","5.03","5.02","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: governance_change, material_agreement","same SEC item: 1.01, 3.02, 3.03, 5.02, 5.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057915","json":"https://secwatch.observer/filing/0001104659-26-057915.json","markdown":"https://secwatch.observer/filing/0001104659-26-057915.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/tm2530822d27_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 7, 2026, the Company filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm"}},{"accession":"0001104659-26-057460","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057460","json":"https://secwatch.observer/filing/0001104659-26-057460.json","markdown":"https://secwatch.observer/filing/0001104659-26-057460.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm"}},{"accession":"0001703056-26-000078","ticker":"ADT","company_name":"ADT Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan","event_type":"other_material","sec_items":["5.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.02, 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001703056-26-000078","json":"https://secwatch.observer/filing/0001703056-26-000078.json","markdown":"https://secwatch.observer/filing/0001703056-26-000078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/adt-20260504.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm"}},{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001104659-26-057976","ticker":"XRN","company_name":"Chiron Real Estate Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057976","json":"https://secwatch.observer/filing/0001104659-26-057976.json","markdown":"https://secwatch.observer/filing/0001104659-26-057976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/tm2613926d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1533615/000110465926057976/0001104659-26-057976-index.htm"}},{"accession":"0001193125-26-214976","ticker":"NKTR","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-05-08T23:59:59+00:00","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","event_type":"other_material","sec_items":["1.01","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214976","json":"https://secwatch.observer/filing/0001193125-26-214976.json","markdown":"https://secwatch.observer/filing/0001193125-26-214976.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the \"Spin Agreements\") with AnaptysBio","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","comparable_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}